Drugs in ATC Class H05BX

Up to Top Level ATC Classes

Up to H - Systemic hormonal preparations, excluding sex hormones and insulins

Up to H05 - CALCIUM HOMEOSTASIS

Up to H05B - ANTI-PARATHYROID AGENTS

Drugs in ATC Class: H05BX - Other anti-parathyroid agents

Tradename	Generic Name
CINACALCET HYDROCHLORIDE	cinacalcet hydrochloride
SENSIPAR	cinacalcet hydrochloride
PARICALCITOL	paricalcitol
ZEMPLAR	paricalcitol
DOXERCALCIFEROL	doxercalciferol
HECTOROL	doxercalciferol
PARSABIV	etelcalcetide

Patent landscape and market dynamics for ATC class H05BX (Other anti-parathyroid agents)

Last updated: June 16, 2026

H05BX market dynamics are driven by a small set of marketed anti-parathyroid and calcium homeostasis therapies, with most revenue concentration tied to calcimimetic and parathyroid-modulating mechanisms. Patent risk for generics and follow-on products varies sharply by active ingredient: products with entrenched composition-of-matter and method-of-use estates face delayed entry, while device-adjacent or formulation-change opportunities can open earlier.

Which drugs sit in ATC class H05BX and what is the market exposure by mechanism?

Featured answer: H05BX is an “other” bucket, so the actionable market picture is built by the specific active ingredients that map into the ATC grouping via national formularies and FDA/EMA labeling.

How to think about H05BX revenue drivers (commercial and lifecycle)

• Demand is typically tied to chronic endocrine disorders with long persistence: primary hyperparathyroidism, secondary hyperparathyroidism in CKD, and related disorders where parathyroid hormone (PTH) suppression is needed.
• Price pressure usually comes from:
  • Loss of exclusivity for a lead calcimimetic or peptide-like product
  • Competitive switching between calcimimetics and conventional vitamin D analogs
  • Health-system formulary tightness for dialysis populations
• Uptake and retention depend on:
  • Dosing schedule (daily vs. titrated regimens)
  • Tolerability (hypocalcemia risk management)
  • Payer coverage and dialysis-center standardization

Key H05BX-relevant active ingredient archetypes

H05BX commonly captures therapies that do not cleanly fit “paricalcitol/calcitriol” or standard vitamin D categories and instead include “parathyroid” pathway modulators. The most commercially meaningful archetype is calcimimetic activity (PTH lowering via calcium-sensing receptor modulation). That generally yields patent-heavy estates with layered follow-on filings covering formulations, dosing regimens, and hypocalcemia mitigation.

What patents protect calcimimetic “parathyroid” agents in H05BX?

Featured answer: Patent protection typically concentrates in composition-of-matter, salt/crystal form, stabilized solid forms, and method-of-treatment claims targeting PTH reduction and hypocalcemia risk control.

Composition-of-matter and solid-state IP (what blocks generic entry)

Calcimimetic estates usually include:

• Core small-molecule composition-of-matter patents (active ingredient)
• Salt form patents (if applicable)
• Solid-state form patents (polymorphs, solvates, hydrates)
• Formulation patents (controlled release, bioavailability enhancement, particle engineering)
• Combination patents (calcimimetic + vitamin D analog, or calcimimetic + phosphate binder where claimed)

Method-of-use and dosing regimen claims (where exclusivity can linger)

Method-of-use patents often claim:

• Treatment of secondary hyperparathyroidism in CKD by administering specified doses over titration windows
• Patient-selection criteria (PTH thresholds, baseline calcium status, dialysis status)
• Hypocalcemia management regimens (calcium supplementation timing, dose adjustment rules)

These claims can survive basic generic “ingredient sameness,” depending on how courts construe infringement and whether carveouts exist for label-equivalent dosing.

Formulation patents: why “same API, different product” still matters

Follow-on formulation patents frequently protect:

• Specific excipient systems that stabilize active ingredient
• Manufacturability improvements
• Improved dissolution rate or exposure profile
• Reduced pill burden or altered strength combinations

For litigation and licensing, this shifts the generic playbook from “is the active the same?” to “is the dosage form and dosing schedule within the claim scope?”

When does exclusivity end for ATC H05BX products, and how do patent timelines control generic launch?

Featured answer: Generic entry timing in H05BX is set by the later of composition-of-matter expiration, formulation/method-of-use patent expirations, and any statutory/regulatory exclusivity on the relevant reference product.

Practical exclusivity timeline structure

For a typical lead H05BX drug:

1. Active ingredient composition-of-matter patents expire first.
2. Solid-state and formulation follow-ons may expire later.
3. Method-of-use patents may expire last, especially if filed in connection with new labeled indications or dosing outcomes.
4. Regulatory exclusivities (New Chemical Entity and/or new dosage forms, depending on the approval history) can delay ANDA submissions and market entry even after patent expiry.

Launch scenarios that affect Paragraph IV value

• If a method-of-use patent expires after composition-of-matter, Paragraph IV challenges can still face injunction risk because courts may find infringement on dosage regimen elements.
• If formulation patents are narrow (specific excipient or release profile), a generic can attempt a design-around by changing formulation while keeping API.
• If claims require patient stratification or specific monitoring logic, generic label equivalence can become a litigation flashpoint.

How many patents cover H05BX drugs, and which assignees dominate the estate?

Featured answer: H05BX patent estates are typically layered and assignee-concentrated, with the original innovator holding the most defensible core patents and later-stage filings often assigned to the same family or corporate affiliates.

Patent estate “shape” used in portfolio diligence

In an innovator calcimimetic-style estate, the bulk of value usually clusters into:

• Active ingredient composition families
• Solid-state families (salt/polymorph)
• Formulation families (dosage form, dissolution, stability)
• Method-of-treatment families (secondary hyperparathyroidism and dosing/titration rules)

What to track for diligence and licensing

• Family size and continuation strategy (number of related filings)
• Jurisdictional coverage (US-only vs global)
• Claim coverage overlap across patents (same dosing logic repeated in multiple families)
• Remaining enforceable term on each patent at the target generic launch date
• Claim construction risk: whether method claims use functional limitations that are hard to design around

Which companies are challenging H05BX patents via Paragraph IV, and what settlement patterns exist?

Featured answer: Paragraph IV challenges for H05BX-style drugs tend to concentrate around the lead innovator’s last-expiring method-of-use or formulation patents, with settlements often involving delayed launch dates or “at-risk” carveouts.

Litigation outcomes that drive market behavior

Common settlement features in H05BX-relevant patent disputes:

• Agreed launch dates aligned to the last expiring patent(s) in the asserted list
• Carveouts for specific strengths or dosage forms not covered by certain patents
• Design-around commitments for formulation differences
• Covenant not to sue in exchange for delayed market entry

What “at-risk” means operationally

At-risk generic launch risks include:

• FDA approval entry with continued injunction exposure in parallel courts
• Switching to a different strength or dosage form to avoid infringement theories
• Rapid label amendment to minimize method-of-use infringement allegations

What is the Orange Book status of H05BX anti-parathyroid agents?

Featured answer: Orange Book entries for H05BX drugs typically list active ingredients, labeled dosage forms/strengths, and corresponding patent codes with expiration data tied to FDA approval and listed patents.

Orange Book diligence checklist for H05BX

• Confirm listed patents per drug/strength at the formulation level
• Map each patent to:
  • Patent type (composition-of-matter vs method-of-use vs formulation)
  • Earliest and latest expiration dates
  • Whether patents are “listed” for the exact dosage form being pursued by a challenger
• Track label changes post-approval that can move infringement analysis for method-of-use patents

What formulations are protected in H05BX, and can generics design around?

Featured answer: Many H05BX estates protect solid-state and formulation profiles. Design-around is feasible when formulation claims are narrow and generic manufacturers can demonstrate non-infringement on release profile or specific solid-form characteristics.

Formulation design-around levers

• Different salt/crystal form (if allowed by formulation science)
• Different particle size distribution or stabilization approach
• Different dissolution profile for the same dose strength
• Different excipient system that avoids claim-limited compositions

Where design-around often fails

• If claims cover broader ranges rather than narrow embodiments
• If the active ingredient solid form is explicitly required in claims
• If method-of-use claims are broad enough that label-equivalent dosing infringes

How does H05BX compare with ATC classes for vitamin D analogs in terms of patent strategy and generic risk?

Featured answer: Compared with classic vitamin D analogs, H05BX calcimimetic-style patents often show heavier method-of-use and patient-management claim focus, which can slow generic entry even after composition-of-matter expiry.

Differential patent “pressure points”

• Vitamin D analogs: often center on active ingredient and certain formulation routes; generic switching can occur faster when method claims are limited.
• H05BX: more likely to include:
  • Dosing titration frameworks
  • Hypocalcemia monitoring and adjustment regimens
  • Patient-selection thresholds for PTH suppression outcomes

What manufacturing and IP barriers affect generic or biosimilar-like competition in H05BX?

Featured answer: H05BX is small-molecule and not biosimilar space, so “biosimilar” risk translates to generics/authorized generics and formulation-only entrants. IP barriers are primarily chemical and formulation manufacturing plus label-driven method-of-use exposure.

Manufacturing constraints that intersect with IP

• Solid-state reproducibility: polymorph stability and batch-to-batch control
• Bioequivalence: exposure targets can be harder if the reference product uses specific formulation tech that is patented
• Scale-up: patent-protected processes (if any) can block “process-to-product” workflows

How do regulatory milestones and FDA pathways shape entry timing for H05BX generics?

Featured answer: ANDA entry timing hinges on Paragraph IV filing windows, patent listing in Orange Book, and any remaining regulatory exclusivity that blocks approval-to-market even if FDA accepts the submission.

FDA pathway mechanics that matter for H05BX

• ANDA with Paragraph IV triggers litigation stays or settlement effects depending on timing.
• If the reference drug is listed in Orange Book with blocking patents, FDA approval can be delayed by litigation or by design-around requirements.
• Label equivalence is crucial for method-of-use infringement risk.

What patent litigation affects H05BX markets most often?

Featured answer: Litigation most often centers on the last-expiring patent families tied to method-of-use dosing regimens and formulation/solid-state identity.

Litigation themes used by courts and parties

• Does the generic’s dosage form infringe formulation claims?
• Does “equivalent” label dosing infringe method claims that specify dose/titration patterns?
• Can challengers design around by changing formulation or by limiting dosing in a way that avoids the claimed regimen?

Key takeaways

• H05BX market exclusivity is primarily driven by calcimimetic-style patent architectures: composition-of-matter plus layered solid-state, formulation, and method-of-use patents.
• Generic timing is usually governed by the last-expiring, most enforceable method-of-use or formulation patents rather than by the earliest active ingredient patent expiry.
• Orange Book status is the operational map for launch risk: patent listing at the specific drug/strength/dosage form level determines whether a Paragraph IV challenge creates actionable pathways or triggers injunction exposure.
• Settlement dynamics in this space commonly trade delayed launch dates for non-infringement and/or design-around commitments tied to formulation and dosing logic.
• Design-around is feasible for narrow formulation claims but often constrained when solid-state identity or label-equivalent method claims dominate infringement theories.

FAQs

1. How do Paragraph IV challenges in ATC H05BX typically target the last-expiring method-of-use patents rather than core composition patents?
2. What Orange Book patent codes and expiration dates should be reviewed to assess H05BX generic launch risk by dosage strength?
3. Which solid-state and formulation patent families most often block “same API” generics in parathyroid pathway drugs?
4. How do label-equivalent dosing regimens increase infringement exposure for method-of-use patents in H05BX?
5. What settlement terms most commonly govern delayed entry for generics seeking FDA approval in H05BX therapeutic areas?

References

(No sources were provided in the prompt, and producing a citation-backed patent and Orange Book landscape without specific drug identifiers would not meet the requirement for hard-data accuracy.)